Abstract:Yang-Hua Xiao, 1, 2 Mei-Fang Liu, 1 Hongwen Wu, 1, 3 De-Rong Xu, 1 Rui Zhao 1 1 Department of Clinical Laboratory, Medical Center for Burn and Plastic Surgery, The First Affiliated Hospital of Nanchang University, Nanchang, People's Republic of China; 2 School of Public Health, Nanchang University, Nanchang, People's Republic of China; 3 Department of Medical Instruments, The First Affiliated Hospital of Nanchang University, Nanchang, People's Republic of China Correspondence: De-Rong Xu; Rui Zhao, Email ; Purpose: Metagenomic next-generation sequencing (mNGS) is a powerful yet unbiased method to identify pathogens in suspected infections. However, little is known about its clinical effectiveness. The present study aimed to assess the efficacy of mNGS in routine clinical practice. Patients and Methods: In this single-center retrospective cohort study, 518 patients with suspected infectious diseases were assessed for inclusion. Among them, each patient had undergone mNGS testing; 407 patients had undergone both microbial culture and mNGS testing. The result of mNGS testing was compared to microbial culture performed concurrently. The diagnostic performance of mNGS was evaluated using the comprehensive clinical diagnosis as the reference standard. Results: There was a significant difference in the positive detection rates of pathogens between mNGS and culture (331/407, 81.3% vs 79/407, 19.4%, P < 0.001). The sensitivity of mNGS was much higher than the culture method (79.5% vs 21.3%, P < 0.001), especially in sample types of sputum and bronchoalveolar lavage fluid (BALF). Notably, the sensitivity of blood mNGS was relatively lower than other sample types (67.4% vs 88.9– 93.8%). Pathogen cfDNA load based on standardized stringently mapped read number at the species level of microorganisms (SDSMRN) was significantly lower in blood than in other sample types from the same patient ( P = 0.0003). Importantly, mNGS directly led to a change of treatment regimen in 142 (27.4%) cases, including antibiotic escalation (15.3%), antibiotic de-escalation (9.1%), and early definitive diagnosis to initiate appropriate treatment (3.1%). Conclusion: Our in-house mNGS platform significantly improved the sensitivity for the diagnosis of infectious diseases. mNGS has the potential to improve clinical outcomes by optimizing antimicrobial therapy. Keywords: mNGS, infections, diagnostic, outcome Infections are the major cause of human deaths worldwide and present a rising threat to public security. 1 Antimicrobial resistance is a major concern that is threatening our ability to treat bacterial infections. 2 Delayed administration of antibiotics significantly increases the in-hospital mortality rate. 3 The tragic outcome of infection highlights the importance of timely diagnosis and appropriate antibiotic treatment of advanced diseases. Conventional microbiologic culture and microscopy remain the gold standard for diagnostics. Full identification of fastidious microorganisms is usually reserved for cases where an isolate is in pure culture. 4,5 However, it is a laborious and time-consuming procedure requiring several days to accomplish. Additionally, the sensitivity of the culture method depends largely on the duration of the infection and whether the patient has previously received antibiotic treatment. 6 For these reasons, rapid and accurate identification of unknown pathogenic microorganisms is critical to guide clinical decision-making about diagnosis and treatment. Molecular methods, such as polymerase chain reaction (PCR), are an alternative method when culture-based microbial detection methods fail. 7,8 However, the preselected target pathogens greatly limit the application of multiplex PCR in identifying infections caused by mixed pathogens. 9 PCR-based analyses may fail to detect unexpected, rare, or novel pathogens unless multiplexed PCRs covering all pathogenic microorganisms are employed. The clinical symptoms and etiologies of multiple infections are complex and diverse, so it is difficult to diagnose using conventional microbial methods. 10,11 This may complicate further treatment (eg, delay antimicrobial treatment, lead to antibiotics overuse, prolong hospitalizations, and increase healthcare costs). Accurate and timely diagnosis is essential for aggressive antimicrobial adjustment. These barriers are not insurmountable obstacles to treating infectious diseases. Metagenomic next-generation sequencing (mNGS) is an untargeted molecular approach that can theoretically detect all potential pathogens in a single experiment. As a -Abstract Truncated-

Utility of Microbial Cell Free DNA Next-Generation Sequencing for Diagnosis and Management of Infectious Diseases

Clinical utility of plasma microbial cell-free DNA sequencing among immunocompromised patients with pneumonia

Diagnostic Value of Microbial Cell-free DNA Sequencing for Suspected Invasive Fungal Infections: A Retrospective Multicenter Cohort Study

Cost-Effectiveness of Plasma Microbial Cell-Free DNA Sequencing When Added to Usual Care Diagnostic Testing for Immunocompromised Host Pneumonia

Cell Free Microbial DNA Utilization at a Children's Hospital

Impact of a New Diagnostic Stewardship Team on Utilization and Interpretation of a Microbial Cell-Free DNA Detection Test

Plasma Microbial Cell-Free DNA Sequencing for Pathogen Detection and Quantification in Children With Musculoskeletal Infections

Clinical Evaluation of Cell-Free and Cellular Metagenomic Next-Generation Sequencing of Infected Body Fluids

Analytical and Clinical Validation of Direct Detection of Antimicrobial Resistance Markers by Plasma Microbial Cell-free DNA Sequencing

Clinical evaluation of cell-free (cf) and cellular metagenomic next-generation sequencing of infected body fluids

Metagenomic next-generation sequencing as a diagnostic tool in the clinical routine of an infectious diseases department: a retrospective cohort study

Comprehensive evaluation of plasma microbial cell-free DNA sequencing for predicting bloodstream and local infections in clinical practice: a multicenter retrospective study

Clinical Metagenomic Sequencing of Plasma Microbial Cell-Free DNA for Febrile Neutropenia in Patients with Acute Leukaemia.

Time-series prediction and detection of potential pathogens in bloodstream infection using mcfDNA sequencing

Cell‐free DNA next‐generation sequencing successfully detects infectious pathogens in pediatric oncology and hematopoietic stem cell transplant patients at risk for invasive fungal disease

Application of cell-free plasma next-generation sequencing technology in the diagnosis and management of pediatric meningitis

Utility of Plasma Cell-Free DNA Next-Generation Sequencing for Diagnosis of Infectious Diseases in Patients with Hematological Disorders.

Clinical Efficacy and Diagnostic Value of Metagenomic Next-Generation Sequencing for Pathogen Detection in Patients with Suspected Infectious Diseases: A Retrospective Study from a Large Tertiary Hospital

Microbial cell-free DNA-sequencing as an addition to conventional diagnostics in neonatal sepsis

Pathogen-agnostic advanced molecular diagnostic testing for difficult-to-diagnose patients – results of an Emerging Infections Network survey of frontline U.S. Infectious Disease Clinicians, May 2023

Noninvasive Diagnosis of Secondary Infections in COVID-19 by Sequencing of Plasma Microbial Cell-Free DNA